Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
Authors
Keywords
-
Journal
Alzheimers Research & Therapy
Volume 10, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-12
DOI
10.1186/s13195-018-0431-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer’s Disease—Studies on Relation to Effective Target Occupancy
- (2017) Torsten Hoffmann et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects
- (2017) Alida A. Gouw et al. NEUROBIOLOGY OF AGING
- GANTENERUMAB TREATMENT REDUCES BIOMARKERS OF NEURONAL AND SYNAPTIC DEGENERATION IN ALZHEIMER’S DISEASE
- (2016) Kaj Blennow et al. Alzheimers & Dementia
- CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
- (2016) Bob Olsson et al. LANCET NEUROLOGY
- Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease
- (2015) Maike Hartlage-Rübsamen et al. ACTA NEUROPATHOLOGICA
- 2015 Alzheimer's disease facts and figures
- (2015) Alzheimers & Dementia
- Neuroinflammation in Alzheimer's disease
- (2015) Michael T Heneka et al. LANCET NEUROLOGY
- The minimum spanning tree: An unbiased method for brain network analysis
- (2015) P. Tewarie et al. NEUROIMAGE
- Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
- (2015) Konstantin Hellwig et al. Alzheimers Research & Therapy
- The trees and the forest: Characterization of complex brain networks with minimum spanning trees
- (2014) C.J. Stam et al. INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY
- Pyroglutamylated Amyloid-β Peptide Reverses Cross β-Sheets by a Prion-Like Mechanism
- (2014) Jason O. Matos et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Activity and Architecture of Pyroglutamate-Modified Amyloid-β (AβpE3-42) Pores
- (2014) Alan L. Gillman et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Amyloid-β and Tau
- (2014) George S. Bloom JAMA Neurology
- Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers
- (2013) Maja A.A. Binnewijzend et al. HUMAN BRAIN MAPPING
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
- (2013) Victor L Villemagne et al. LANCET NEUROLOGY
- Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
- (2012) Justin M. Nussbaum et al. NATURE
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics
- (2011) Hanneke de Waal et al. NEUROBIOLOGY OF AGING
- Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease
- (2010) Lars M. Ittner et al. NATURE REVIEWS NEUROSCIENCE
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
- (2009) Clifford R Jack et al. LANCET NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started